Exhibit 99.1

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Rule 3.19A.2

 

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

 

Introduced 30/9/2001.             Amended 01/01/11

 

 Name of Entity:  Radiopharm Theranostics Limited (ASX: RAD)
 ABN:  57 647 877 889

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director:  Riccardo Canevari
  Date of Last Notice:  19 December 2025

 

Part 1 - Change of director’s relevant interests in securities

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or Indirect Interest Direct  
     

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the relevant interest.

 N/A  
     
Date of change 24 August 2026
           
No. of securities held prior to change     Shares Options  
    Direct 20,029,986 185,287,299  
    Indirect 2,650,000 -  
    Total 22,679,986 185,287,299 
           
Class Listed Options    
Number acquired

NIL

    
Number disposed 1,875,000 Listed Options    

Value/Consideration

Note:

If consideration is non-cash, provide details and estimated valuation

 N/A  

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 1

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

 

No. of securities held after change     Shares Options  
    Direct 20,029,986 183,412,299  
    Indirect 2,650,000 -  
    Total 22,679,986 183,412,299 
     

Nature of change

Example:
on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

 Expiry of Listed Options (Exp 24 Aug 2026)

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract N/A
Nature of interest N/A

Name of registered holder

(if issued securities)

 N/A
Date of change N/A

No. and class of securities to which interest related prior to change

Note: Details are only required for a contract in relation to which the interest has changed

 N/A
Interest acquired N/A
Interest disposed N/A

Value/Consideration

Note: If consideration is non-cash, provide details and an estimated valuation

 N/A
Interest after change N/A

 

+ See chapter 19 for defined terms. 
  
Appendix 3Y Page 201/01/2011

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Part 3 – Closed period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 3

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Rule 3.19A.2

 

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

 

Introduced 30/9/2001.        Amended 01/01/11

 

 Name of Entity:

 Radiopharm Theranostics Limited (ASX: RAD)
 ABN:  57 647 877 889

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

 Name of Director:

  Paul Hopper
 Date of Last Notice:  19 December 2025

 

Part 1 - Change of director’s relevant interests in securities

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or Indirect Interest Direct  
     

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the relevant interest.

 N/A  
     
Date of change 24 August 2026
           
No. of securities held prior to change     Shares Options  
    Direct 53,900,000 53,642,000  
    Indirect 93,821,428 9,017,518  
    Total 147,721,428

62,659,518

           
Class Listed Options    
Number acquired

NIL

    
Number disposed 27,500,000 Listed Options    

Value/Consideration

Note:

If consideration is non-cash, provide details and estimated valuation

 N/A  

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 1

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

No. of securities held after change     Shares Options  
    Direct 53,900,000 26,142,000  
    Indirect 93,821,428 9,017,518  
    Total 147,721,428 35,159,518  
   

Nature of change

Example:

on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

 Expiry of Listed Options (Exp 24 Aug 2026)

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract N/A
Nature of interest N/A

Name of registered holder
(if issued securities)

 N/A
Date of change N/A

No. and class of securities to which interest related prior to change

Note: Details are only required for a contract in relation to which the interest has changed

 N/A
Interest acquired N/A
Interest disposed N/A

Value/Consideration

Note: If consideration is non-cash, provide details and an estimated valuation

 N/A
Interest after change N/A

 

+ See chapter 19 for defined terms. 
  
Appendix 3Y Page 201/01/2011

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Part 3 – Closed period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?

 No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A

  

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 3

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Rule 3.19A.2

 

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

 

Introduced 30/9/2001.             Amended 01/01/11

 

 Name of Entity:  Radiopharm Theranostics Limited (ASX: RAD)
 ABN:  57 647 877 889

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director:  Ian Turner
  Date of Last Notice:  31 March 2026

 

Part 1 - Change of director’s relevant interests in securities

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or Indirect Interest Direct and indirect  
     

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the relevant interest.

 Superannuation fund  
     
Date of change 24 August 2026
           
No. of securities held prior to change     Shares Options  
    Direct 2,530,595 23,081,926  
    Indirect 7,454,697 820,422  
    Total 9,985,292 23,902,348 
           
Class Listed Options    
Number acquired NIL    
Number disposed

Direct

    
  1,125 000 Listed Options    
 

 

Indirect

    
  750,000 Listed Options    

Value/Consideration

Note:

If consideration is non-cash, provide details and estimated valuation

 N/A  

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 1

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

 

No. of securities held after change     Shares Options  
    Direct 2,530,595 21,956,926  
    Indirect 7,454,697 70,422  
    Total 9,985,292

22,027,348

     

Nature of change

Example:
on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

 Expiry of Listed Options (Exp 24 Aug 2026)

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract N/A
Nature of interest N/A

Name of registered holder

(if issued securities)

 N/A
Date of change N/A

No. and class of securities to which interest related prior to change

Note: Details are only required for a contract in relation to which the interest has changed

 N/A
Interest acquired N/A
Interest disposed N/A

Value/Consideration

Note: If consideration is non-cash, provide details and an estimated valuation

 N/A
Interest after change N/A

 

+ See chapter 19 for defined terms. 
  
Appendix 3Y Page 201/01/2011

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Part 3 – Closed period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 3

 

Appendix 3Y
Change of Director’s Interest Notice

 

Rule 3.19A.2

 

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

 

Introduced 30/9/2001.           Amended 01/01/11

 

Name of Entity: Radiopharm Theranostics Limited (ASX: RAD)
ABN: 57 647 877 889

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director: Hester Larkin
Date of Last Notice: 18 December 2024

 

Part 1 - Change of director’s relevant interests in securities

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or Indirect Interest Direct and indirect  
     

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the relevant interest.

 N/A  
     
Date of change

24 August 2026

           
No. of securities held prior to change     Shares Options  
    Direct 550,000 10,175,002  
    Indirect 94,247  -  
    Total 644,247 10,175,002  
           
Class

Listed Options

  
           
Number acquired   NIL  
           
Number disposed   275,000 Listed Options  
           

Value/Consideration

Note:

If consideration is non-cash, provide details and estimated valuation

NIL

  

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 1

 

Appendix 3Y
Change of Director’s Interest Notice

 

No. of securities held after change     Shares Options  
    Direct 550,000 9,900,002  
    Indirect 94,247  -  
    Total 644,247 9,900,002  
   

Nature of change

Example:

on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

 Expiry of Listed Options (Exp 24 Aug 2026)

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract N/A
Nature of interest N/A

Name of registered holder

(if issued securities)

 N/A
Date of change N/A

No. and class of securities to which interest related prior to change

Note: Details are only required for a contract in relation to which the interest has changed

 N/A
Interest acquired N/A
Interest disposed N/A

Value/Consideration

Note: If consideration is non-cash, provide details and an estimated valuation

 N/A
Interest after change N/A

 

+ See chapter 19 for defined terms. 
  
Appendix 3Y Page 201/01/2011

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Part 3 – Closed period 

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?

 No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 3